Novonesis (Novozymes) B (NSISBC.XD)

DKK 410.0

(-0.89%)

Total Liabilities Summary of Novonesis (Novozymes) B

  • Novonesis (Novozymes) B's latest annual total liabilities in 2023 was 14.04 Billion DKK , up 2.07% from previous year.
  • Novonesis (Novozymes) B's latest quarterly total liabilities in 2024 Q2 was 31.68 Billion DKK , down -0.01% from previous quarter.
  • Novonesis (Novozymes) B reported annual total liabilities of 13.75 Billion DKK in 2022, up 9.51% from previous year.
  • Novonesis (Novozymes) B reported annual total liabilities of 12.56 Billion DKK in 2021, up 35.56% from previous year.
  • Novonesis (Novozymes) B reported quarterly total liabilities of 31.68 Billion DKK for 2024 Q2, down -0.01% from previous quarter.
  • Novonesis (Novozymes) B reported quarterly total liabilities of 14.04 Billion DKK for 2023 FY, up 2.07% from previous quarter.

Annual Total Liabilities Chart of Novonesis (Novozymes) B (2023 - 2019)

Historical Annual Total Liabilities of Novonesis (Novozymes) B (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 14.04 Billion DKK 2.07%
2022 13.75 Billion DKK 9.51%
2021 12.56 Billion DKK 35.56%
2020 9.26 Billion DKK 3.45%
2019 8.95 Billion DKK 0.0%

Peer Total Liabilities Comparison of Novonesis (Novozymes) B

Name Total Liabilities Total Liabilities Difference